Eckert & Ziegler Radiopharma has received EU approval for Theralugand, its radiopharmaceutical medicinal product.
Theralugand provides high-purity lutetium-177 produced in compliance with good manufacturing practice (GMP) standards with specifications designed for the labeling of therapeutic radiopharmaceuticals, the vendor stated in a press release on 27 November.
"The approval unlocks its potential to support innovative cancer therapies such as those targeting neuroendocrine tumors and metastatic prostate cancer. The previous, GMP-certified lutetium-177 was limited to investigational use in clinical studies," the company noted.
